UCLA Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, United States.
UCLA Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine, United States.
J Psychosom Res. 2024 Apr;179:111625. doi: 10.1016/j.jpsychores.2024.111625. Epub 2024 Feb 23.
Biofeedback is a therapeutic treatment model that teaches self-regulation of autonomic functions to alleviate stress-related symptoms. "Long COVID" refers to chronic physical and cognitive sequelae post-SARS-CoV-2 infection. This study examined the efficacy of a six-week intervention, consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback, for alleviating mood symptoms, somatic symptoms and sleep disturbance of patients diagnosed with long COVID.
Data were collected from 20 adult participants aged 22-63 (M = 44.1, SD = 12.2) with varying long COVID symptoms. Within this single arm design, 16 of the 20 participants completed all six sessions of biofeedback; 14 completed an assessment at the three-month post-treatment time point.
Participants self-reported significant improvements in somatic, anxiety, and depressive symptoms, sleep quality, quality of life, and number of "bad days" immediately after the intervention and three months later (Cohen's d effect size (ES) = 1.09-0.46). Reduced number of medical doctor visits (ES = 0.85) and prescription drug use over the last month (odds ratio = 0.33), as well as improved emotional wellbeing (ES = 0.97) were observed at the three-month time point only.
Results suggest that this short, readily scalable intervention can be potentially efficacious in alleviating symptoms of long COVID. Despite notable improvements, the major limitation of this study is its lack of control group. While a randomized trial merits study, biofeedback appears to be a brief, effective, non-invasive, and low-cost treatment option for patients with chronic somatic symptoms secondary to SARS-CoV-2 infection.
govID: NCT05120648.
生物反馈是一种治疗模式，通过教授自主功能的自我调节来缓解与压力相关的症状。“长新冠”是指 SARS-CoV-2 感染后的慢性身体和认知后遗症。本研究旨在检验为期六周的干预措施的疗效，该干预措施每周进行一次，每次一小时，结合心率变异性和体温生物反馈，以缓解被诊断为长新冠的患者的情绪症状、躯体症状和睡眠障碍。
从 20 名年龄在 22-63 岁之间（M=44.1，SD=12.2）、具有不同长新冠症状的成年参与者中收集数据。在这项单臂设计中，20 名参与者中有 16 名完成了所有六次生物反馈治疗；其中 14 名在治疗后三个月完成了评估。
参与者自我报告称，在干预后和三个月后，躯体症状、焦虑和抑郁症状、睡眠质量、生活质量和“糟糕日子”的数量均有显著改善（Cohen's d 效应量（ES）=1.09-0.46）。在三个月时，还观察到就诊次数（ES=0.85）和处方药使用（比值比=0.33）减少，情绪健康状况改善（ES=0.97）。
结果表明，这种简短、易于扩展的干预措施可能对缓解长新冠症状有效。尽管有显著改善，但本研究的主要局限性在于缺乏对照组。虽然随机试验值得研究，但生物反馈似乎是一种简短、有效、非侵入性且低成本的治疗选择，适用于继发于 SARS-CoV-2 感染的慢性躯体症状患者。
govID：NCT05120648。
